Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $550.80 | Total: $2,754.00 |
| 1 | 10 | $466.56 | Total: $4,665.60 |
| 1 | 25 | $395.28 | Total: $9,882.00 |
| 1 | 50 | $336.96 | Total: $16,848.00 |
| 1 | 100 | $291.60 | Total: $29,160.01 |
Overview
Flovagatran (TGN 255) is an orally active, potent, and selective inhibitor of thrombin and parenteral direct factor II.Flovagatran is used to study venous thromboembolism.
Chemical Properties
| Molecular Formula | C27H36BN3O7 |
| Molecular Weight | 525.4 |
| CAS Numbers | 871576-03-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C([C@@H](CC1=CC=CC=C1)NC(OCC2=CC=CC=C2)=O)(=O)N3[C@H](C(N[C@@H](CCCOC)B(O)O)=O)CCC3 |
Storage and Handling
0C Short Term, -20C Long Term
References
Nelson DA, et al. Pharmacodynamic and efficacy profile of TGN 255, a novel direct thrombin inhibitor, in canine cardiopulmonary bypass and simulated mitral valve repair. J Extra Corpor Technol. 2008 Jun;40[2] 116-22.